Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Polycythemia Vera Clinical Trial

— PV  

Official title:

A Randomized Controlled Study Evaluating the Efficacy and Safety of Pegylated Interferon α-2b in Combination With Ruxolitinib vs. Pegylated Interferon α-2b Monotherapy for Treating Hydroxyurea-resistant/Intolerant Polycythemia Vera

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05870475
• Other study ID #: IITPV-2023-01
• Status: Recruiting
• Phase: Phase 2
• Start date: May 30, 2023
• Est. completion date: May 31, 2028

Study information

• Verified date: May 2023
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Lei Zhang, MD
• Phone: 8602223909240
• Email: zhanglei1[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

Description:

Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

The subjects will be randomly divided into two groups:

pegylated interferon alpha-2b combined with ruxolitinib group: pegylated interferon alpha-2b at a starting dose of 180ug will be administered subcutaneously once a week; ruxolitinib at a starting dose of 10mg will be administered orally twice daily.

pegylated interferon alpha-2b group: pegylated interferon alpha-2b at a starting dose of 180ug will be administered subcutaneously once a week.

If complete hematologic remission is not achieved after 12 weeks of treatment with pegylated interferon alpha-2b alone, the subject may be switched to the pegylated interferon alpha-2b combined with ruxolitinib group. If ruxolitinib is not tolerated, the subject may be switched to the pegylated interferon alpha-2b group alone.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 94
• Est. completion date: May 31, 2028
• Est. primary completion date: March 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• =18 years old.

• Male or Female.

• Meets the diagnostic criteria for Polycythemia Vera according to WHO-2022.

• Resistant or intolerant to hydroxyurea (based on the 2013 European LeukemiaNet criteria).

• Have not previously received interferon preparations or ruxolitinib treatment, or the washout period between the last use of interferon preparations or ruxolitinib and the first use of the study drug should not be less than 4 weeks.

• Patients with indications for cytoreductive therapy.

• During screening, female hemoglobin (HGB) =10g/dL, male hemoglobin (HGB) =11g/dL; neutrophil count =1.5×109/L; platelet count =100×109/L.

• Voluntary written informed consent.

Exclusion Criteria:

• Symptomatic splenomegaly;

• Contraindications to interferon or ruxolitinib therapy;

• Severe or significant comorbidities that may affect the participant's ability to participate in the study, as determined by the investigator;

• History of major organ transplantation;

• Pregnant or breastfeeding women;

• History or current diagnosis of autoimmune thyroid disease (patients with controlled hypothyroidism on oral thyroid hormone replacement therapy may be included);

• Documented evidence of any other autoimmune disease (such as active hepatitis, systemic lupus erythematosus, antiphospholipid antibody syndrome, or autoimmune arthritis);

• Clinically significant bacterial, fungal, mycobacterial, parasitic, or viral infection such as active hepatitis or HIV infection (patients with acute bacterial infections requiring antibiotic treatment should be deferred from screening/enrollment until completion of antibiotic treatment);

• Evidence of severe retinopathy or clinically significant ophthalmologic disease (due to diabetes or hypertension);

• Current clinically significant depression or history of depression, or any suicidal attempt or tendency during screening;

• Active bleeding or thrombotic complications;

• History of any malignant tumor within the past 5 years (except for stage 0 chronic lymphocytic leukemia [CLL], cured basal cell carcinoma, squamous cell carcinoma, and superficial melanoma);

• History of alcohol or substance abuse within the past year;

• Presence of blasts in the peripheral blood within the past 3 months;

• Use of any investigational drug or participation in any other clinical trial within 4 weeks prior to the first dose of the study drug, or failure to recover from any effects of previously administered study drugs;

• The investigator deems the presence of any concurrent condition that may jeopardize the safety of the participant or the compliance to the protocol.

Related Conditions & MeSH terms

• Polycythemia
• Polycythemia Vera

Intervention

Drug:
• Ruxolitinib
Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon a-2b alone group is allowed.
• Pegylated interferon a-2b
Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon a-2b alone, cross-over to the pegylated interferon a-2b plus ruxolitinib group is allowed.

Locations

Country	Name	City	State
China	Institute of Hematology & Blood Diseases Hospital	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Hematology & Blood Diseases Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes of T lymphocytes	Change in the proportion and gene expression profile of T lymphocytes	From the start of study treatment (Week 0) up to the end of Week 52.
Other	Changes of B lymphocytes	Change in the proportion and gene expression profile of B lymphocytes	From the start of study treatment (Week 0) up to the end of Week 52.
Other	Changes of dendritic cells	Change in the proportion and gene expression profile of dendritic cells	From the start of study treatment (Week 0) up to the end of Week 52.
Primary	The cumulative complete hematologic response (CHR) rate	The proportion of patients who can achieve CHR ( defined as hematocrit lower than 45% without phlebotomies; platelet count < 400×109/L, WBC count < 10×109/L for at least 12 weeks) among all patients.	From the start of study treatment (Week 0) up to the end of Week 24.
Secondary	Cumulative CHR rates at Week 36.	Cumulative CHR rates at Week 36 will be compared between the two groups.	From the start of study treatment (Week 0) up to the end of Week 36.
Secondary	Cumulative CHR rates at Week 52.	Cumulative CHR rates at Week 52 will be compared between the two groups.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	Time to CHR	The time of reaching CHR will be compared between the two groups.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	The CHR rates after crossover	The CHR rates within 52 weeks after crossover	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	The rate of reduction in JAK2V617F, CALR, or MPL gene mutation burden.	The rate of reduction in JAK2V617F, CALR, or MPL gene mutation burden will be compared between the two groups.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	Impact of therapy on non-driver mutations	To compare the proportion of subjects that display change on key non-driver biomarkers of the disease-DNMT3A, ASXL1, TET2 or other mutations.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	Change of splenomegaly	All subjects with palpable splenomegaly at baseline will undergo ultrasound examination.; For subjects with palpable splenomegaly at baseline: Improvement - no palpable splenomegaly during clinical treatment visits; No progress - ultrasound examination during clinical treatment visits shows an increase in spleen size of = 25%; Progress - Ultrasound examination during clinical treatment visits shows an increase in spleen size of>25%.	From the start of study treatment (Week 0) up to the end of Week 52.]
Secondary	Change of bone marrow pathology	Bone marrow histological remission defined as the presence of age-adjusted normocellularity and disappearance of trilinear hyperplasia, and absence of grade 1 reticulin fibrosis; no remission defined as the persistence of trilinear hyperplasia; progression defined as disease transformation into post-PV myelofibrosis, myelodysplastic syndrome or acute leukemia.	From the start of study treatment (Week 0) up to the end of Week 52
Secondary	The incidence of major thrombotic events	To compare the incidence of major thrombotic events between the two groups.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	The incidence of major bleeding events	To compare the incidence of major bleeding events between the two groups.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	The incidence of progressing to acute leukemia	The incidence of progressing to acute leukemia will be compared between the two groups.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	Change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score	To compare the proportion of subjects that display change in Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (0-100 scores, higher scores mean a worse outcome) between different treatment groups.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	Change of quality of life using QLQ-C30 V3.0 questionnaire.	The QLQ-C30 V3.0 questionnaire consists of 30 questions, with questions 1-28 scoring 1-4 and questions 29 and 30 scoring 1-7. Therefore, this questionnaire has a minimum score of 30 and a maximum score of 126, and the score is directly proportional to the quality of life.	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	Change of microcirculation disturbance	The rate of patients with improvement in microcirculation disturbance (such as pruritus, headache, dizziness, chest tightness, erythematous limb pain and limb paresthesia) will be compared between the two groups	From the start of study treatment (Week 0) up to the end of Week 52.
Secondary	Specific pre-defined toxicity	To compare incidence of specific pre-defined toxicity including fatigue, flu-like symptoms, dizziness, injection site necrosis, dyspnea, pain, depression, blurred Vision, insomnia, anorexia, weight Loss, weakness, pruritis, sweating, fever, decreased Libido, hot Flashes, flushing, infection,	From the start of study treatment (Week 0) up to the end of Week 52.